NASONEX ALLERGY AND CONGESTION 50 MCG
MOMETASONE FUROATE : 50 MCG · DIN 02410524 · MERCK CANADA INC
Health Canada status: CANCELLED PRE MARKET
What is NASONEX ALLERGY AND CONGESTION?
NASONEX ALLERGY AND CONGESTION 50 MCG contains MOMETASONE FUROATE : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02410524, held by MERCK CANADA INC, supplied as SPRAY, METERED DOSE for NASAL administration. Health Canada currently lists it as cancelled pre market, status dated 17-Aug-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NASONEX ALLERGY AND CONGESTION used for?
Treatment of the symptoms of seasonal or perennial allergic rhinitis in adults and children 12 years of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02410524 |
|---|---|
| Brand name | NASONEX ALLERGY AND CONGESTION |
| Generic / active ingredient | MOMETASONE FUROATE : 50 MCG |
| Manufacturer | MERCK CANADA INC |
| Strength | 50 MCG |
| Dosage form | SPRAY, METERED DOSE |
| Route of administration | NASAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R01AD09 MOMETASONE |
| AHFS class | 52:08.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 17-Aug-2021 |
How is it administered?
Adults and children ≥12: 2 sprays (50 mcg/spray) in each nostril once daily (200 mcg total). Maintenance: 1 spray per nostril. Max: 4 sprays per nostril. Shake well and prime before use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 2° and 25°C and protected from light. Do not freeze.
How is it supplied?
Supplied in a single pack (1 bottle) or dual pack (2 bottles). Available in 60 and 140 metered dose sizes.
Contraindications
Hypersensitivity to the drug or ingredients. Use with caution in patients with active/quiescent tuberculous infections, untreated fungal, bacterial, systemic viral infections, or ocular herpes simplex.
Warnings and precautions
Risk of adrenal insufficiency when transferring from systemic steroids. Avoid use with untreated nasal mucosal infection or recent nasal surgery/trauma until healing. Monitor for vision changes.
What can be used instead?
Other Canadian products sharing ATC code R01AD09 MOMETASONE. 6 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-MOMETASONE | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | MARKETED | DIN 02403587 |
| MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SANIS HEALTH INC | MARKETED | DIN 02519127 |
| MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02551756 |
| NASONEX | 50 MCG | SPRAY, METERED DOSE | ORGANON CANADA INC. | MARKETED | DIN 02238465 |
| SANDOZ MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02449811 |
| TEVA-MOMETASONE | 50 MCG | SPRAY, METERED DOSE | TEVA CANADA LIMITED | MARKETED | DIN 02475863 |
| MOSASPRAY | 50 MCG | SPRAY, METERED DOSE | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02455870 |
| NASAL ALLERGY AND CONGESTION RELIEF | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | APPROVED | DIN 02451905 |
Who else supplies MOMETASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MOMETASONE appears in 2383 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.